Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,470 shares of the company’s stock after selling 3,708 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Zoetis were worth $4,957,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of ZTS. Schwab Charles Investment Management Inc. raised its position in Zoetis by 6.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,595,919 shares of the company’s stock valued at $99,554,000 after buying an additional 101,287 shares during the period. Wetherby Asset Management Inc. raised its position in Zoetis by 4.2% in the second quarter. Wetherby Asset Management Inc. now owns 12,277 shares of the company’s stock valued at $766,000 after buying an additional 495 shares during the period. Bright Rock Capital Management LLC bought a new position in Zoetis during the second quarter valued at $4,679,000. Cigna Investments Inc. New raised its position in Zoetis by 41.3% in the second quarter. Cigna Investments Inc. New now owns 28,231 shares of the company’s stock valued at $1,764,000 after buying an additional 8,245 shares during the period. Finally, Rockland Trust Co. bought a new position in Zoetis during the second quarter valued at $7,763,000. Institutional investors own 94.51% of the company’s stock.
Zoetis Inc. (NYSE ZTS) opened at 59.73 on Friday. The company has a market capitalization of $29.21 billion, a price-to-earnings ratio of 33.76 and a beta of 1.02. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85. The stock has a 50 day moving average price of $62.20 and a 200-day moving average price of $58.00.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. Zoetis’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.49 EPS. Equities analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current year.
WARNING: “Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Sells 3,708 Shares of Zoetis Inc. (NYSE:ZTS)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/12/mitsubishi-ufj-kokusai-asset-management-co-ltd-sells-3708-shares-of-zoetis-inc-nysezts.html.
Several equities analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 target price on shares of Zoetis in a report on Monday, August 7th. Deutsche Bank AG lowered Zoetis from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Tuesday, July 25th. Stifel Nicolaus restated a “buy” rating and set a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. Cowen and Company set a $70.00 target price on Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Finally, Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. Zoetis has a consensus rating of “Buy” and a consensus target price of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.